Ultomiris And Successor Key To AstraZeneca’s Rare Disease Ambitions
Room For Growth In Rare Diseases
Executive Summary
Having completed its $39bn takeover of Alexion, AstraZeneca must now demonstrate its ability to maximize revenues and performance from the US rare disease specialist.
You may also be interested in...
Alexion’s Phase III Data Position Ultomiris For Expansion Into Myasthenia Gravis
As its acquisition by AstraZeneca moves toward closure, Alexion plans to file the Soliris follow-on for generalized myasthenia gravis in the US, EU and Japan. But potential competition awaits in the C5 inhibitor and FcRn antagonist classes.
How AstraZeneca Overcame US Anti-Trust Obstacles For Alexion Deal
While the sector is gripped by fears that overly zealous anti-competition regulators pose a threat to future M&A biopharma deals, AstraZeneca's acquisition of Alexion has sauntered through the US FTC's review. Its CFO Marc Dunoyer tells Scrip why the company is not surprised.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.